Cancer Drug May Double As an Arthritis Treatment
Posted on: Thursday, 2 March 2006, 18:00 CST
WASHINGTON (AP) -- The nation's best-selling cancer drug has won federal approval as a treatment for rheumatoid arthritis patients for whom other, older drugs don't work, Genentech Inc. and Biogen Idec Inc. said Wednesday.
The Food and Drug Administration action comes more than eight years after the agency initially approved Rituxan to treat non- Hodgkin's lymphoma.
The two companies said Rituxan should be used by patients who haven't had success with a class of rheumatoid arthritis drugs called tumor necrosis factor, or TNF, blockers. Those drugs include Enbrel, Remicade and Humira.
Source: Deseret News (Salt Lake City)
Related Articles
- The Drug Information Center Arthritis Project: Providing Patients With Interactive and Reliable Arthritis Internet Education
- WHO Programme for International Drug Monitoring
- Abnormal Drug Response: Opportunities for Risk Reduction Through Pharmacogenetics
- Advances in Single-Patient Trials for Drug Treatment Optimization and Risk Management*
- 12 Freed for Texas Drug Bust Appeals
- 12 Freed in Appeal of Texas Drug Busts
- 'Rapid Detox' Breaks Drug Habits Quickly
- Advisers: Arthritis Drug Not Too Risky
- 55 Charged With Selling Drug Gear Online
- ADHD Drug Prescriptions Vary by ZIP Code
Rating: 2.9 / 5 (11 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds